Table 2.

Cox regression between genomic alterations and recurrence after BCG therapy (n = 62, 32 events)

Gene	HR	95% CI	p value	False discovery rate
ARID1A	3.14	(1.51, 6.51)	0.002	0.04
FGFR3	1.63	(0.79, 3.37)	0.188	0.9
KRAS	0.79	(0.18, 3.38)	0.75	0.94
ERBB2	0.56	(0.21, 1.46)	0.236	0.9
PIK3	0.62	(0.26, 1.52)	0.299	0.9
TSC1	0.84	(0.29, 2.43)	0.755	0.94
TP53	1.09	(0.51, 2.32)	0.819	0.94
CDKN2A	0.68	(0.24, 1.94)	0.469	0.94
CDKN1A	0.95	(0.33, 2.73)	0.924	0.97
CCND1	0.72	(0.17, 3.03)	0.656	0.94
STAG2	1.13	(0.46, 2.78)	0.785	0.94
KDM6A	0.75	(0.36, 1.53)	0.424	0.94
EP300	1.13	(0.34, 3.71)	0.847	0.94
CREBBP	2.26	(0.92, 5.55)	0.076	0.8
TERT	1.25	(0.51, 3.11)	0.624	0.94
ERCC2	0.52	(0.18, 1.49)	0.226	0.9
KMT2D	1	(0.38, 2.62)	0.994	0.99
RBM10	1.42	(0.43, 4.68)	0.568	0.94
FAT1	0.32	(0.04, 2.37)	0.265	0.9
FBXW7	0.73	(0.22, 2.39)	0.597	0.94
MGA	0.86	(0.26, 2.84)	0.799	0.94

BCG = bacillus Calmette-Guérin; CI = confidence interval; HR = hazard ratio.